Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.

Authors

null

Madelyn Burkart

Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Madelyn Burkart , Nicholas Demetriou , Ashwin Sunderraj , Shou Ma , Jane N. Winter , Leo I. Gordon , Jonathan Moreira , Reem Karmali , Ishan Roy

Organizations

Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Feinberg School of Medicine, Northwestern University, Chicago, IL, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Northwestern University Feinberg School Of Medicine, Division Of Hematology/Oncology, Department Of Medicine, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Shirley Ryan AbilityLab, Chicago, IL

Research Funding

No funding received
None.

Background: Advancements in treatment over the last decade have greatly improved survival in B cell non-Hodgkin’s lymphoma (NHL), yet not all patients (pts) benefit the same. Non-Hispanic Black (NHB), uninsured and lower socioeconomic status pts continue to suffer worse survival. However, the impact of neighborhood deprivation on disability has not been explored. We aimed to assess the association between neighborhood deprivation and disability free survival (DFS) in NHL pts. Methods: 258 aggressive NHL pts treated between 2005-2020 were included. Pts without documented follow up were excluded. Race/ethnicity was categorized as non-Hispanic white (NHW), Hispanic, NHB and other. Primary outcomes included progression free survival (PFS), overall survival (OS) and DFS. DFS was defined as time to needing any rehabilitative, home-health or skilled nursing services immediately following induction therapy, indicating disability and lack of functional independence. Neighborhood deprivation was assigned using the national Area Deprivation Index (ADI), a validated measure classifying neighborhood adversity. Pts were categorized into high (67-99), intermediate (34-66) or low (1-33) ADI scores, with least disadvantaged designated by lower scores. Kaplan-Meier analyses were used to compare PFS, OS and DFS. Results: Demographic data is shown in the table; 45% were female, 65% were NHW, 10% were NHB, 8% were Hispanic and 10% were other. Median age at diagnosis was 57 years. There was no difference in PFS or OS between racial/ethnic groups (p=0.91 and p=0.23 respectively). Payor source influenced both PFS and OS (p<0.001 and p<0.001 respectively), with self-pay associated with worse PFS and OS. Neighborhood deprivation based on ADI did not influence PFS (p=0.33) or OS (p=0.76). High ADI score was associated with worse DFS compared to lower ADI scores (p=0.03). ADI score differed significantly based on race/ethnicity (p<0.0001), with more NHB pts residing in areas of high ADI scores (40% vs 5% NHW vs 10% Hispanic). There was no association between ADI score and a pt’s ECOG performance status, IPI score or albumin at diagnosis (p=0.87, p=0.78 and p=0.59 respectively). Conclusions: NHL pts with higher neighborhood adversity experience more disability after treatment despite similar survival. Further work is needed to better understand how neighborhood factors are contributing to disability before community-level strategies for improvement can be developed.

Total N
(N=258)
Low ADI
(N=153)
Intermediate ADI
(N=76)
High ADI
(N=29)
P-value
Gender (%)
Male
Female

142
116

57
62

34
53

9
13
P=0.25
Age (%)
>/= 60 years old
< 60 years old

133
124

53
66

35
24

12
10
P=0.09
Race/ethnicity (%)
NHW
NHB
Hispanic
Other

168
25
21
27

65
24
52
52

29
36
38
33

5
40
10
15
P<0.0001
Diagnosis (%)
DLBCL
MCL

197
61

59
61

31
26

10
13
P=0.69
IPI score (%)
Low
Low-intermediate
High-intermediate
High

74
89
54
41

59
61
54
63

27
31
31
29

14
8
15
7
P=0.78

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7564)

DOI

10.1200/JCO.2023.41.16_suppl.7564

Abstract #

7564

Poster Bd #

115

Abstract Disclosures